Share
NYBC Ventures expects to advance the development of cellular therapies. Credit: qimono from Pixabay.

Early-stage life sciences investment fund NYBC Ventures has launched its new $50m fund to speed up developments in the fields of blood and cellular therapies and related technologies.

The New York Blood Center (NYBC) has provided the investment for the inaugural fund.

Related Company Profiles

View all

NYBC Ventures will focus on investment in therapeutics, devices and new technologies to address issues in benign haematology, transfusion medicine and infectious disease.

The fund expects to advance the development of a number of therapeutics, as well as provide platforms and technologies to improve patients’ lives.

It also seeks to support strategic partnerships to further expand NYBC’s reach.

NYBC Ventures uses a patient capital model with a flexible method to fund vehicles and structures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has created consolidated scientific and due diligence teams to assess investment opportunities.

A team led by Christopher Hillyer, NYBC president and CEO and NYBC Ventures general partner, manages NYBC Ventures.

It works with NYBC’s researchers, manufacturing teams and operations staffs.

NYBC Ventures’ current portfolio consists of Catena Biosciences, HealthQuest Capital, KaloCyte, Thymmune Therapeutics, StealthCo and STRM Bio.

Hillyer stated: “This is the first venture fund solely dedicated to advancing innovation in blood and cell-based therapies and technologies.

“NYBC Ventures provides companies more than capital, offering access to world-renowned researchers and their labs, cell manufacturing capacity and source materials.”

NYBC currently offers lifesaving blood products, pharmaceuticals, clinical and laboratory services along with transfusion capabilities to major medical organisations in the US.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.